Lupkynis
voclosporin · Otsuka Pharmaceutical Netherlands B.V.
AUTHORISED IN THE EUWhat Lupkynis is used for
Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Lupkynis
- Active substance
- voclosporin
- Disease area
- Lupus Nephritis
- Medicine group
- Immunosuppressants
- ATC code
- L04AD03
- Marketing authorisation holder
- Otsuka Pharmaceutical Netherlands B.V.
- Authorised in the EU since
- 2022
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lupkynis used for?
Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
What is the active substance in Lupkynis?
Lupkynis contains voclosporin.
Who makes Lupkynis?
The EU marketing authorisation holder is Otsuka Pharmaceutical Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU